Liminatus Pharma, Inc. Warrants
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 201… Read more
Liminatus Pharma, Inc. Warrants (LIMNW) - Net Assets
Latest net assets as of September 2025: $-1.65 Million USD
Based on the latest financial reports, Liminatus Pharma, Inc. Warrants (LIMNW) has net assets worth $-1.65 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.34 Million) and total liabilities ($2.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.65 Million |
| % of Total Assets | -122.6% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Liminatus Pharma, Inc. Warrants - Net Assets Trend (2021–2024)
This chart illustrates how Liminatus Pharma, Inc. Warrants's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Liminatus Pharma, Inc. Warrants (2021–2024)
The table below shows the annual net assets of Liminatus Pharma, Inc. Warrants from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-15.87 Million | -0.48% |
| 2023-12-31 | $-15.79 Million | -46.11% |
| 2022-12-31 | $-10.81 Million | -104.24% |
| 2021-12-31 | $254.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Liminatus Pharma, Inc. Warrants's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 361365000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.76 Million | % |
| Other Comprehensive Income | $-160.68K | % |
| Other Components | $51.80K | % |
| Total Equity | $-15.87 Million | 100.00% |
Liminatus Pharma, Inc. Warrants Competitors by Market Cap
The table below lists competitors of Liminatus Pharma, Inc. Warrants ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gammon Pakistan Ltd
KAR:GAMON
|
$557.48 |
|
Eco Depot Inc
PINK:ECDP
|
$557.87 |
|
People’s Merchant Finance PLC
CM:PMBN0000
|
$558.32 |
|
Dandot Cement Company Ltd
KAR:DNCC
|
$558.39 |
|
Sassy Gold Corp.
OTCQB:SSYRD
|
$554.43 |
|
CENTRAL PETROLEUM (C9J.SG)
STU:C9J
|
$553.96 |
|
Caledonian Holdings PLC
LSE:CHP
|
$553.83 |
|
TANFIELD GRP
BE:XS3A
|
$553.65 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Liminatus Pharma, Inc. Warrants's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 0 to -15,869,899, a change of -15,869,899.
- Net loss of 2,904,299 reduced equity.
- Share repurchases of 1,802,869 reduced equity.
- Other comprehensive income decreased equity by 160,677.
- Other factors decreased equity by 11,002,054.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.90 Million | -18.3% |
| Share Repurchases | $1.80 Million | -11.36% |
| Other Comprehensive Income | $-160.68K | -1.01% |
| Other Changes | $-11.00 Million | -69.33% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Liminatus Pharma, Inc. Warrants's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $7.39 | $0.06 | x |
| 2022-12-31 | $0.00 | $0.06 | x |
| 2023-12-31 | $0.00 | $0.06 | x |
| 2024-12-31 | $-2.21 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Liminatus Pharma, Inc. Warrants utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 1.71% | 0.00% | 0.00x | 1.08x | $-21.12 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.93 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.98 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.32 Million |
Industry Comparison
This section compares Liminatus Pharma, Inc. Warrants's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Liminatus Pharma, Inc. Warrants (LIMNW) | $-1.65 Million | 1.71% | N/A | $557.28 |
| Abcam plc (ABCZF) | $148.21 Million | 17.14% | 0.19x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $7.74 Million | 76.78% | 1.27x | $327.05K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $-46.26 Million | 0.00% | 0.00x | $5.68 Million |
| Adamas Trust, Inc. (ADAMG) | $2.31 Billion | -12.50% | 1.02x | $2.10 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $13.74 Million | 0.00% | 2.67x | $10.13 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $108.93 Million | 26.27% | 3.34x | $2.11 Million |
| Forafric Global PLC Warrants (AFRIW) | $29.21 Million | -43.40% | 9.60x | $2.20 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $282.84 Million | 1.97% | 0.05x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $3.02 Billion | 7.45% | 0.13x | $117.77K |
| Alvotech Warrant (ALVOW) | $-412.77 Million | 0.00% | 0.00x | $31.83 Million |